Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04182100
Recruitment Status : Recruiting
First Posted : December 2, 2019
Last Update Posted : February 6, 2020
Sponsor:
Information provided by (Responsible Party):
PharmaEssentia Japan K.K.

Brief Summary:
This is a Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.

Condition or disease Intervention/treatment Phase
Polycythemia Vera (PV) Drug: P1101 Drug: Low-dose aspirin Procedure: Phlebotomy Phase 2

Detailed Description:

Eligible patients will be treated with P1101, starting at 100 μg (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit <45%, platelets <400 x 10^9/L and leukocytes <10 x 10^9/L). The maximum recommended single dose is 500 μg injected every two weeks.

At week 36 (month 9) and week 52 (month 12), the primary study endpoint, phlebotomy-free CHR, will be analyzed. After completion of the 52-week study duration, provision and administration of P1101, collection of the long-term follow up information (blood parameters, molecular and cytogenetic data, safety parameters and as also the optional bone marrow data) will be continued until the drug becomes commercially available for all study subjects..

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of P1101 (ropeginterferon alfa-2b) once every 2 weeks
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Single Arm Study of Efficacy and Safety of P1101 for Polycythemia Vera (PV) Patients for Whom the Current Standard of Treatment is Difficult to Apply
Actual Study Start Date : December 20, 2019
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : April 30, 2021


Arm Intervention/treatment
Experimental: P1101
Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
Drug: P1101
P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit <45%, platelets <400 x 10^9/L and leukocytes <10 x 10^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
Other Name: ropeginterferon alfa-2b

Drug: Low-dose aspirin
Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
Other Name: Low-dose acetylsalicylic acid

Procedure: Phlebotomy
Phlebotomy is performed aiming at a hematocrit < 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.




Primary Outcome Measures :
  1. Proportion of subjects achieving durable phlebotomy-free complete hematological response (CHR) at Month 12 [ Time Frame: 12 months ]

    The primary efficacy outcome measure is the proportion of subjects achieving durable phlebotomy-free complete hematologic response (CHR) at Month 12.

    Durable phlebotomy-free CHR is defined as any subject achieving phlebotomy-free CHR at Month 9 and maintaining the response up to Month 12.

    A responder in sense of a primary outcome measure is a subject who has met all the following criteria at the time points:

    • Hematocrit <45% phlebotomy-free (absence of phlebotomy during the previous 3 months)
    • Platelet count ≤400 x 10^9/L,
    • WBC count ≤10 x 10^9/L


Secondary Outcome Measures :
  1. Changes in Hct from baseline [ Time Frame: Baseline, 3 months, 6 months, 9 months and 12 months ]
    Hct will be recorded every 3 months.

  2. Changes in WBC count from baseline [ Time Frame: Baseline, 3 months, 6 months, 9 months and 12 months ]
    WBC count will be recorded every 3 months.

  3. Changes in Plt count from baseline [ Time Frame: Baseline, 3 months, 6 months, 9 months and 12 months ]
    Plt count will be recorded every 3 months.

  4. Changes in spleen size from baseline [ Time Frame: Baseline, 3 months, 6 months, 9 months and 12 months ]
    Spleen size will be recorded every 3 months.

  5. Time to requiring no phlebotomy [ Time Frame: Up to 12 months ]
    Time to requiring no phlebotomy is recorded.

  6. Time required to first response [ Time Frame: Up to 12 months ]
    Time required to first response is defined as time to achieve complete hematological response (CHR) without phlebotomy.

  7. Duration of response maintenance [ Time Frame: Up to 12 months ]
    Duration of maintained complete hematologic response (CHR) since first achievement of CHR after administration of the study drug will be calculated.

  8. Proportion of subjects without thrombotic or hemorrhagic events [ Time Frame: Up to 12 months ]
    Thrombotic or hemorrhagic events will be recorded any time during the study. The proportion of subjects without thrombotic or hemorrhagic events is defined as the proportion of subjects experienced no thrombotic and hemorrhagic events during the study period (12 months).

  9. Change of JAK2 mutant allelic burden over time vs. baseline [ Time Frame: Baseline, 3 months, 6 months, 9 months and 12 months ]
    Quantitative JAK2 measurements at screening, Months 3, 6, 9 and 12 (central laboratory) for subjects who signed consent form. Change of JAK2 allelic burden over time will be assessed.

  10. PK of P1101 [ Time Frame: Up to 12 months ]

    Trough concentration is the measured concentration of a drug at the end of a dosing interval at steady state every 2 weeks.

    Additionally, serum concentration is measured at hours 0, 24, 48, 96 and 168 after administration at Week 0 and Week 28.



Other Outcome Measures:
  1. Status of bone marrow histological remission (optional) [ Time Frame: 0 month, 12 months ]
    Status of bone marrow histological remission defined as the disappearance of hypercellularity (age-adjusted), trilineage growth (panmyelosis) and absence of >grade 1 reticulin fibrosis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients ≥20 years old
  2. Patients diagnosed with PV according to the WHO 2008 or WHO 2016 criteria
  3. PV patients for whom the current standard of treatment is difficult to apply. (Patients with a documented history of refractory to HU are excluded.)

    • Younger patients (long-term treatment is anticipated)
    • Patients who are categorized as low risk, but cytoreduction is recommended due to disease-related signs and symptoms (headache, dizziness, pruritus, night sweats, fatigue, erythromelalgia, vision disorders, scintillating scotoma, early satiety, abdominal distension).
    • Patients with HU intolerance
  4. Total HU treatment duration shorter than 3 years (cumulatively) at screening
  5. For cytoreduction naïve patients only: PV in need of cytoreductive treatment, defined by fulfilling as one or more of the following criteria at baseline:

    • at least one previous well documented major cardiovascular PV-related event in the medical history
    • poor tolerance of phlebotomy (defined as a phlebotomy/ procedure-related adverse event causing significant adverse impact on the patient and limiting ability to apply phlebotomy with the intention to keep Hct <45%)
    • frequent need of phlebotomy (more than one phlebotomy within last month prior entering the study)
    • platelet counts greater than 1000 x 10^9/L (for two measurements within the month prior treatment start)
    • leukocytosis (WBC>10 x 10^9/L for two measurements within the month prior treatment start)
  6. Adequate hepatic function defined as bilirubin ≤1.5 x upper limit normal (ULN), international normalized ratio (INR) ≤1.5 x ULN, albumin >3.5 g/dL, alanine aminotransferase (ALT) ≤2.0 x ULN, aspartate aminotransferase (AST) ≤2.0 x ULN at screening
  7. Hemoglobin (HGB) ≥10 g/dL at screening
  8. Neutrophil count ≥1.5 x 10^9/L at screening
  9. Serum creatinine ≤1.5 x ULN at screening
  10. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales (Patients with a borderline of HADS score [score 7 but <10] or patients with necessity [expected benefits are higher than the risks] based on investigators' discretion are required to receive following assessment by psychiatric specialist to confirm the eligibility for IFNα therapy.).
  11. Males and females of childbearing potential, as well as all women <2 years after the onset of menopause, must agree to use an acceptable form of birth control until 28 days following the last dose of the study drug
  12. Written informed consent obtained from the patient or the patient's legal representative, and ability for the patient to comply with the requirements of the study

Exclusion Criteria:

  1. Patients with symptomatic splenomegaly
  2. Previous use of IFNα for any indication
  3. Any contraindications or hypersensitivity to interferon-alfa
  4. Co-morbidity with severe or serious conditions which may impact patient participation in the study in investigator's opinion
  5. History of major organ transplantation
  6. Pregnant or lactating females
  7. Patients with any other medical conditions, which in the opinion of the Investigator would compromise the results of the study or may impair compliance with the requirements of the protocol

    7-1. History or presence of thyroid dysfunction (clinical symptoms of hyper- or hypo-thyroidism) of the autoimmune origin, except late stages cases on the oral thyroid substitution therapy, where potential exacerbation under interferon therapy will not constitute any further harm to the patient

    7-2.Documented autoimmune disease (e.g., hepatitis, idiopathic thrombocytopenic purpura [ITP], scleroderma, psoriasis, or any autoimmune arthritis)

    7-3. Clinically relevant pulmonary infiltrates and pneumonitis at screening, patients with a history of interstitial pulmonary disease

    7-4. Active infections with systemic manifestations (e.g., bacterial, fungal, hepatitis B [HBV], hepatitis C [HCV], or human immunodeficiency virus [HIV]) at screening)

    7-5. Evidence of severe retinopathy (e.g., cytomegalovirus retinitis [CMV], macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension) based on the ophthalmological assessment by specialists.

    7-6. Uncontrolled depression

    7-7. Previous suicide attempts or at any risk of suicide at screening

  8. Uncontrolled diabetes mellitus (HbA1c level of > 7% at baseline)
  9. History of any malignancy within for the past 5 years
  10. History of alcohol or drug abuse within the last year
  11. History or evidence of post polycythemia vera-myelofibrosis (PPV-MF), essential thrombocythemia, or any non-PV MPN
  12. Presence of circulating blasts in the peripheral blood within the last 3 months
  13. Use of any investigational drug(s), or investigational drug combinations <4 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04182100


Contacts
Layout table for location contacts
Contact: Narihisa MIyachi +81-3-6866-9531 narihisa_miyachi@pharmaessentia.com

Locations
Layout table for location information
Japan
Ehime University Hospital Not yet recruiting
Toon-shi, Ehime, Japan, 791-0295
Mie University Hospital Not yet recruiting
Tsu-shi, Mie, Japan
Osaka University Hospital Not yet recruiting
Suita-shi, Osaka, Japan, 565-0871
Juntendo University Hospital Recruiting
Bunkyo-ku, Tokyo, Japan, 113-8431
NTT Medical Center Tokyo Not yet recruiting
Shinagawa-ku, Tokyo, Japan, 141-8625
Tokyo Medical University Hospital Not yet recruiting
Shinjuku-ku, Tokyo, Japan, 160-0023
Keio University Hospital Not yet recruiting
Shinjuku-ku, Tokyo, Japan, 160-8582
University of Yamanashi Hospital Recruiting
Chuo-shi, Yamanashi, Japan, 409-3898
Sponsors and Collaborators
PharmaEssentia Japan K.K.
Layout table for additonal information
Responsible Party: PharmaEssentia Japan K.K.
ClinicalTrials.gov Identifier: NCT04182100    
Other Study ID Numbers: A19-201
First Posted: December 2, 2019    Key Record Dates
Last Update Posted: February 6, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PharmaEssentia Japan K.K.:
Myeloproliferative Neoplasms
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycythemia Vera
Polycythemia
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Bone Marrow Diseases
Myeloproliferative Disorders
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics